

# Richard Grose

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4663909/publications.pdf>

Version: 2024-02-01

27  
papers

3,564  
citations

516710

16  
h-index

526287

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

6506  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibroblast growth factor signalling: from development to cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 116-129.	28.4	2,172
2	Fibroblast growth factor signaling in tumorigenesis. <i>Cytokine and Growth Factor Reviews</i> , 2005, 16, 179-186.	7.2	371
3	Nuclear translocation of <sc>FGFR</sc>1 and <sc>FGF</sc>2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. <i>EMBO Molecular Medicine</i> , 2014, 6, 467-481.	6.9	133
4	Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. <i>Trends in Cell Biology</i> , 2015, 25, 221-233.	7.9	129
5	Hallmarks of cancerâ€™the new testament. <i>Open Biology</i> , 2021, 11, 200358.	3.6	104
6	FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. <i>Journal of Cell Biology</i> , 2012, 197, 801-817.	5.2	101
7	Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. <i>Journal of Pathology</i> , 2016, 239, 286-296.	4.5	98
8	Dysregulated FGF signalling in neoplastic disorders. <i>Seminars in Cell and Developmental Biology</i> , 2016, 53, 126-135.	5.0	69
9	The ins and outs of fibroblast growth factor receptor signalling. <i>Clinical Science</i> , 2014, 127, 217-231.	4.3	53
10	Centrosome amplification mediates small extracellular vesicle secretion via lysosome disruption. <i>Current Biology</i> , 2021, 31, 1403-1416.e7.	3.9	41
11	Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. <i>World Journal of Gastroenterology</i> , 2014, 20, 8471.	3.3	37
12	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. <i>Cell Reports</i> , 2018, 22, 2469-2481.	6.4	34
13	A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 50.	5.0	31
14	Tumour microenvironment 3D-modelling: simplicity to complexity and back again. <i>Trends in Cancer</i> , 2021, 7, 1033-1046.	7.4	31
15	Emerging Roles of Fibroblast Growth Factor 10 in Cancer. <i>Frontiers in Genetics</i> , 2018, 9, 499.	2.3	24
16	Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. <i>Cells</i> , 2021, 10, 847.	4.1	19
17	Biological Significance and Targeting of the FGFR Axis in Cancer. <i>Cancers</i> , 2021, 13, 5681.	3.7	18
18	Fibroblast growth factorâ€™mediated crosstalk in cancer etiology and treatment. <i>Developmental Dynamics</i> , 2017, 246, 493-501.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer. <i>Cell Proliferation</i> , 2022, 55, e13249.	5.3	15
20	Quantitative Super-Resolution Imaging for the Analysis of GPCR Oligomerization. <i>Biomolecules</i> , 2021, 11, 1503.	4.0	12
21	Macrophages induce malignant traits in mammary epithelium via IKK $\mu$ /TBK1 kinases and the serine biosynthesis pathway. <i>EMBO Molecular Medicine</i> , 2020, 12, e10491.	6.9	11
22	FGF signalling facilitates cervical cancer progression. <i>FEBS Journal</i> , 2022, 289, 3440-3456.	4.7	11
23	The Obscure Potential of AHNAK2. <i>Cancers</i> , 2022, 14, 528.	3.7	11
24	Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 43.	3.7	7
25	Grb-ing receptor activation by the tail. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 113-114.	8.2	7
26	Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 287-293.	0.7	3
27	Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. <i>European Journal of Surgical Oncology</i> , 2022, 48, 383-390.	1.0	3